David Tougeron: Nal-IRI/LV5-FU Versus Paclitaxel as Second-line Therapy
David Tougeron, Professor at Poitiers University Hospital, shared a post on LinkedIn:
“Our last published FFCD PRODIGE trial, that I have coordinated, evaluating second line chemotherapy in metastatic oesophagus squamous cell carcinoma. Both paclitaxel and 5FU Naliri have poor efficacy but paclitaxel had a better safety profile.”
Title: Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)
Authors: David Tougeron, Laurent Mineur, Aziz Zaanan, Melissa Kadi, Catherine Poisson Ligeza, Vincent Bourgeois, Jérôme Martin-Babau, Aurélie Fadin, Véronique Jestin le Tallec, Valérie Ly Lebrun, Olivier Dubreuil, Faiza Khemissa Akouz, Elsa Thimonier, Olivier Bouché, Astrid Lièvre, Frédéric Di Fiore, Thierry Lecomte, Côme Lepage, Vincent Hautefeuille
Read the Full Article.
More posts featuring David Tougeron.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023